在董事出售股票后，Corcept Therapeutics 的股价下跌，但分析师维持“买入”评级。 Corcept Therapeutics' stock dips after director sells shares, but analysts maintain a "Buy" rating.

Corcept Therapeutics 在一名董事出售价值 130,812 美元的股票后股价下跌。 Corcept Therapeutics saw its stock price drop after a director sold shares worth $130,812. 尽管如此,该公司最近报告的收入比预期的要好,分析师对该公司的“Buy”评级为65.25美元,价格目标是65.25美元。 Despite this, the company recently reported better-than-expected earnings and has a "Buy" rating from analysts with a price target of $65.25. 感应器研制出治疗严重病情的药物,包括其主要产品Korlym,用于治疗Cushing综合症和2型糖尿病患者的高血糖。 Corcept develops drugs for severe medical conditions, including its main product, Korlym, which treats hyperglycemia in patients with Cushing's syndrome and type 2 diabetes.